ArticlePharmaceutics2023
Encapsulation of Thymol in Gelatin Methacryloyl (GelMa)-Based Nanoniosome Enables Enhanced Antibiofilm Activity and Wound Healing.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Thymol and carvacrol againstFrontiers in pharmacology · 2024Pooled it
- Thymol as a natural monoterpenoid antibacterial agent: a comprehensive review of applications and current advances.Archives of microbiology · 2026Review
- Article
- Sustainable Applications of Thymol: Advances in Formulation Technologies, Drug Delivery Systems, and Food Preservation Strategies.Food science & nutrition · 2026Review
- Dietary Supplements in Public Health: Benefits, Risks, and Emerging Gel/Hydrogel Delivery Systems.Gels (Basel, Switzerland) · 2026Review
- Comparative Kinetic Modeling and Mathematical Analysis of Monoterpene Release from Nanocarrier Systems.AAPS PharmSciTech · 2026Article
- Decellularized bone matrix-enriched 3D-printed GelMA scaffold as a cell-homing platform: analysis using an artificial pulp chamber model.Clinical oral investigations · 2026Article
- Liposome-based drug delivery systems for skin wound healing: a promising drug delivery strategy.Frontiers in bioengineering and biotechnology · 2026Review
- Lights and Shadows of Essential Oil-Derived Compounds: Antimicrobial and Anti-Inflammatory Properties of Eugenol, Thymol, Cinnamaldehyde, and Carvacrol.Current issues in molecular biology · 2025Review
- Enhanced antibacterial activity of 3D-printed niosome-curcumin/ceftizoxime scaffolds against drug-resistant pathogens.BMC microbiology · 2025Article
- Potentials and Challenges in Development of Vesicular Phospholipid Gel as a Novel Dermal Vehicle for Thymol.Pharmaceutics · 2025Article
- Advancements in GelMA bioactive hydrogels: Strategies for infection control and bone tissue regeneration.Theranostics · 2025Review
- Essential oils: a potential alternative with promising active ingredients for pharmaceutical formulations in chronic wound management.Inflammopharmacology · 2024Review
- Greener healing: sustainable nanotechnology for advanced wound care.Discover nano · 2024Review
- Progress in Topical and Transdermal Drug Delivery Research-Focus on Nanoformulations.Pharmaceutics · 2024Review
- Thymol as a Component of Chitosan Systems-Several New Applications in Medicine: A Comprehensive Review.Plants (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-healing wounds impose huge cost on patients, healthcare, and society, which are further fortified by biofilm formation and antimicrobial resistance (AMR) problems. Here, Thymol, an herbal antimicrobial agent, is utilized to combat AMR. For efficient delivery of Thymol gelatin methacryloyl (GelMa), a hydrophilic polymeric hydrogel with excellent biocompatibility combined with niosome was used to encapsulate Thymol. After optimization of the niosomal Thymol (Nio-Thymol) in the company of GelMa (Nio-Thymol@GelMa) to achieve maximum entrapment efficiency, minimum size, and low polydispersity index, the Thymol release peaked at 60% and 42% from Nio-Thymol@GelMa in medium with pH values of 6.5 and 7.4 after 72 h, respectively. Furthermore, Nio-Thymol@GelMa demonstrated higher antibacterial and anti-biofilm activity than Nio-Thymol and free Thymol against both Gram-negative and Gram-positive bacteria. Interestingly, compared with other obtained formulations, Nio-Thymol@GelMa also led to greater enhancement of migration of human dermal fibroblasts in vitro, and higher upregulation of the expression of certain growth factors such as FGF-1, and matrix metalloproteinases such as MMP-2 and MMP-13. These results suggest that Nio-Thymol@GelMa can represent a potential drug preparation for Thymol to enhance the wound healing process and antibacterial efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.